RXi Pharmaceuticals Profile

1.24
USD 0.04  3.33%
15%
50%

RXi Pharmaceuticals exotic insider transaction detected

RXi Pharmaceuticals Corporation insider trading alert for general transaction of common stock by Opko Health Inc, the corporate stakeholder, on August 21, 2018. This event was filed by Rxi Pharmaceuticals Corp with SEC on 2013-03-13. Initial filing of beneficial ownership - SEC Form 3 [view details]   

RXi Pharmaceuticals Summary

RXi Pharmaceuticals Corporation (RXII) is traded on Nasdaq Capital Markets in USA. It is located in 257 Simarano Drive and employs 15 people. The company currently falls under 'Nano-Cap' category with current market capitalization of 6.7 M. RXi Pharmaceuticals Corporation conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 4.38 M outstanding shares of which 464.13 K shares are at this time shorted by private and institutional investors with about 2.92 trading days to cover. RXI PHARMACEUTICA currently holds about 5.32 M in cash with (8.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.21.
Check RXi Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

RXi Pharmaceuticals Target Price Odds Analysis

Odds Below 1.24HorizonTargetOdds Above 1.24
8.42%30 days 1.24 91.52%
Based on normal probability distribution, the odds of RXi Pharmaceuticals to move above current price in 30 days from now is about 91.52% (This RXi Pharmaceuticals Corporation probability density function shows the probability of RXi Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

RXi Pharmaceuticals Top Holders

RXi Pharmaceuticals Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Anson Funds Management LpWarrants218 K421 K
Sabby Management LlcCommon Shares168.5 K325 K
Sg Americas Securities LlcCommon Shares118.4 K228 K
View RXi Pharmaceuticals Diagnostics

RXi Pharmaceuticals Risk Profiles

RXi Pharmaceuticals Key Fundamentals

RXi Pharmaceuticals Against Markets

RXi Pharmaceuticals Current Ratings

RXi Pharmaceuticals Corporation 30 Days Performance Scores

Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
Financial Distress (0 to 100%)
94 
Equity ratings for RXi Pharmaceuticals Corporation are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts. RXi Pharmaceuticals operates under Biotechnology classification in USA and traded on Nasdaq Capital Markets. It employs 15 people. more
NameRXi Pharmaceuticals Corporation
President CEO, DirectorGeert CauwenberghView All
Analyst Consensus
Macroaxis Advice
InstrumentUSA Stock View All
Business Address257 Simarano Drive
ExchangeNasdaq Capital Markets
SectorHealthcare
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.rxipharma.com
Phone508 767 3861
CurrencyUSD - US Dollar

RXi Pharmaceuticals Directors

RXi Pharmaceuticals Corporate Directors

Robert Bitterman Director
Keith Brownlie Director
Jonathan Freeman Independent Director
Additionally take a look at Your Equity Center. Please also try Piotroski F Score module to get piotroski f score based on binary analysis strategy of nine different fundamentals.
Search macroaxis.com